Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. It occurs when antibodies interfere with acetylcholine receptors at the neuromuscular junction, impairing signal transmission between nerves and muscles.

The Myasthenia Gravis session examines the pathophysiology, diagnosis, and management of MG, focusing on immune dysregulation, antibody diversity, and neuromuscular physiology. Researchers explore how the complement system and thymic abnormalities contribute to disease onset and progression.

At the Myasthenia Gravis Conference, neurologists, immunologists, and clinical researchers present updates on therapeutic advances including acetylcholinesterase inhibitors, corticosteroids, immunosuppressants, and biologic therapies targeting B-cell and complement pathways. Cutting-edge gene and cell therapies are also discussed as potential curative approaches.

This session is designed for neurologists, researchers, and rehabilitation professionals addressing neuromuscular disorders. Attendees gain insight into precision treatment, early detection, and patient-centered care.

Current findings in Neuromuscular Diseases and Disorders research continue to expand understanding of synaptic transmission, immune modulation, and motor recovery—offering hope for long-term remission.